BUDGET IMPACT ANALYSIS OF VENETOCLAX FOR MANAGEMENT OF ACUTE MYELOID LEUKEMIA FROM THE PERSPECTIVE OF THE SOCIAL SECURITY AND THE PRIVATE SECTOR IN ARGENTINA

被引：0
|
作者：
Palacios, A. [1 ]
Espinola, N. [1 ]
Gonzalez, J. M. [1 ]
Rivas, M. M. [2 ]
Rojas-Roque, C. [1 ]
Kanevsky, D. [3 ]
Morisset, P. [3 ]
Augustovski, F. [1 ]
Pichon-Riviere, D. A. [1 ]
Bardach, A. [1 ]
机构：
[1] Inst Clin Effectiveness & Hlth Policy IECS, Buenos Aires, DF, Argentina
[2] Hosp Univ Austral, Pilar, Argentina
[3] AbbVie, Buenos Aires, DF, Argentina
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSB43
引用
收藏
页码：S68 / S68
页数：1
相关论文
共 50 条
  • [1] Budget impact analysis of venetoclax for the management of acute myeloid leukemia from the perspective of the social security and the private sector in Argentina
    Palacios, Alfredo
    Espinola, Natalia
    Gonzalez, Juan Martin
    Rojas-Roque, Carlos
    Rivas, Maria Marta
    Kanevski, Diego
    Morisset, Pierre
    Augustovski, Federico
    Pichon-Riviere, Andres
    Bardach, Ariel
    PLOS ONE, 2024, 19 (01):
  • [2] Budget impact and cost per responder analysis of upadacitinib for the treatment of moderate to severe atopic dermatitis from the perspective of the social security and the private sector in Argentina
    Espinola, Natalia
    Cairoli, Federico Rodriguez
    Rojas-Roque, Carlos
    Luna, Paula Carolina
    Kanevsky, Diego
    Migliazza, Valeria
    Pichon-Riviere, Andres
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2025, 25 (01) : 101 - 111
  • [3] Budget Impact analysis of ponatinib for the management of patients with chronic myeloid leukemia
    Basile, Michele
    Rumi, Filippo
    Cicchetti, Americo
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2021, 8 : 87 - 95
  • [4] BUDGET IMPACT ANALYSIS OF UPADACITINIB FOR MODERATE-TO-SEVERE ATOPIC DERMATITIS FOR SOCIAL SECURITY AND PRIVATE THIRD-PARTY PAYERS IN ARGENTINA
    Kanevsky, D.
    Espinola, N.
    Cairoli, Rodriguez F.
    Rojas-Roque, C.
    Luna, P.
    Migliazza, V
    Pichon-Riviere, D. A.
    VALUE IN HEALTH, 2023, 26 (06) : S115 - S115
  • [5] A FIVE-YEAR BUDGET IMPACT ANALYSIS OF THE INCLUSION OF ETONOGESTREL IMPLANT FROM THE PRIVATE HEALTH SECTOR PERSPECTIVE IN BRAZIL
    Coutinho, M. B.
    Haas, L. C.
    Carvalho, L. C.
    Risso, F.
    VALUE IN HEALTH, 2017, 20 (05) : A283 - A284
  • [6] COST-MINIMIZATION AND BUDGET IMPACT ANALYSIS OF VENETOCLAX PLUS OBINUTUZUMAB COMPARED WITH ACALABRUTINIB IN THE FIRST LINE AND R/R CHRONIC LYMPHOCYTIC LEUKEMIA FROM THE BRAZILIAN PRIVATE HEALTHCARE PERSPECTIVE
    Marinato, A.
    Takao, A.
    Campos, L.
    Silva, R.
    Tanaka, S.
    VALUE IN HEALTH, 2022, 25 (12) : S126 - S127
  • [7] BUDGET IMPACT ANALYSIS OF THE INCORPORATION OF MIDOSTAURIN FOR FLT3-POSITIVE ACUTE MYELOID LEUKEMIA (AML) IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM (BPHS).
    Buehler, A.
    Kim, H. S. J.
    Fahham, L.
    Matsuo, A. L.
    VALUE IN HEALTH, 2019, 22 : S470 - S470
  • [8] Budget Impact Analysis of Gemtuzumab Ozogamicin for the Treatment of CD33-Positive Acute Myeloid Leukemia
    Carla Mamolo
    Verna Welch
    Roland B. Walter
    Joseph C. Cappelleri
    James Brockbank
    Matthew Cawson
    Chris Knight
    Michele Wilson
    PharmacoEconomics, 2021, 39 : 121 - 131
  • [9] Budget Impact Analysis of Gemtuzumab Ozogamicin for the Treatment of CD33-Positive Acute Myeloid Leukemia
    Mamolo, Carla
    Welch, Verna
    Walter, Roland B.
    Cappelleri, Joseph C.
    Brockbank, James
    Cawson, Matthew
    Knight, Chris
    Wilson, Michele
    PHARMACOECONOMICS, 2021, 39 (01) : 121 - 131
  • [10] ECONOMIC IMPACT OF DIRECT COSTS ASSOCIATED WITH STROKE IN PATIENTS WITH TYPE 2 DIABETES FROM THE PERSPECTIVE OF THE SOCIAL SECURITY AND PRIVATE HEALTHCARE PROVIDERS IN ARGENTINA
    Zambon, F.
    VALUE IN HEALTH, 2024, 27 (06) : S101 - S101
12345